昨日因传闻大涨的内房股普遍回调，物管股跟跌，苹果概念股、影视娱乐股、职业教育股普遍走低，此前连创新高的新消费概念估老铺黄金大跌超11%。 | 行业热力图 × | 领涨板块 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 电讯设备 | 能源储存装置 -1.31% | 证券及经纪 +5.89% | 互动媒体及服 -1.08% | | | | 银行 -1.01% | 线上零售商 +1.48% | 电讯服务 +0.76% | +0.76% | | | | | | | | | | | | 家庭电器 | 非酒精饮料 | | | | | | | | 药品 -0.54% | +1.40% | -0.45% | | | | | | | 汽车 +0.79% | | 黄金及贵金属 | 游戏软件 | 4 | | | | | | | 生物技术 +2.75% | +1.31% | -0.43% | | | | 数码解决方案服务 +0.19% | 保险 +2.07% | 油气生产商 +0.29% | | | 常规电力 -0. ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 近日，由中国科学院脑科学与智能技术卓越创新中心、华大生命科学研究院、基因组多维解析技术全国重点实验室、华中科技大学苏州 脑空间信息研究院等国内外 30 多家科研机构组成的超 300 人的科研团队， 在国际顶尖学术期刊 Cell （4篇） 及其子刊 Neuron （4 篇） 、 Developmental Cell （2篇） 集中刊发了 10 篇脑图谱研究论文。 该系列研究成果于 7 月 10 日在 Cell Press 官网以专题形式隆重推介，并登上 Cell 期刊封面。同时， Cell 还刊发了一篇由该项目团队 撰写的评述文章，系统总结了系列成果的科学发现与未来方向。 这些研究揭示了小鼠和灵长类动物大脑中多种细胞类型及其连接情况，封面图片展示了一只猕猴凝视着繁星点点的宇宙，其中星座勾勒 出大脑的轮廓。 本文重点介绍其中发表在 Cell 期刊的 4 篇研究论文。 全球首个猕猴屏状核多模态图谱， 揭秘意识产生的关键脑区 论文题目 ： Single-cell spatial transcriptome atlas and whole-brain connectivity o ...

Company Overview - Tian Da Pharmaceutical focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical industry [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - Tian Da Pharmaceutical utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and expand its market reach [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% compared to the previous year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Tian Da Pharmaceutical's price-to-earnings (P/E) ratio is -4.73, ranking 138th in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 2.79 [3] - The company has underperformed the Hang Seng Index, with a cumulative decline of 20.12% this year, compared to the index's increase of 19.78% [2] Industry Context - The pharmaceutical and biotechnology industry has an average P/E ratio of 2.79, with a median of 6.7 [3] - Competitors in the industry include other pharmaceutical companies with varying P/E ratios, such as Jingxin Pharmaceutical at 0.86 and Dongrui Pharmaceutical at 3.03 [3]

金十数据7月11日讯，今日，港股三大指数开盘冲高，盘中恒生指数涨幅逼近2%，尾盘稍有回落。截至 收盘。恒生指数收涨0.46%，恒生科技指数收涨0.61%，国企指数收涨0.22%。中资券商、生物医药、加 密货币等概念股涨幅居前；除此以外，保险、芯片、港口运输、家电、有色金属等概念日内收涨。内房 股今日回调，内银股早盘上涨，午盘持续走弱；除此以外、电池、电力设备、新消费、苹果等概念股跌 幅居前。个股方面。药明康德(02359.HK)报盈喜收涨10%，中州证券(01375.HK)收涨47%，市值突破100 亿港元，人气个股金涌投资(01328.HK)今日收涨32%。 港股收评：恒指收涨0.46%，医药股走强 ...

研 行 行业周报 业 半年报预告密集披露，关注业绩表现 ——医药生物行业周报 究 分析师： 侯雅楠 SAC NO： S1150524120001 2025 年 07 月 11 日 医药生物 投资要点： 证券分析师 行业要闻 侯雅楠 022-23839211 houyn@bhzq.com （1）国家医疗保障局公布《2025 年国家基本医疗保险、生育保险和工伤保 险药品目录及商业健康保险创新药品目录调整工作方案》等相关文件； 研究助理 近三月行业指数走势图 （2）默沙东 100 亿美元收购 Verona，获得慢性阻塞性肺病（COPD）重磅 新药； （3）7.2mg 司美格鲁肽申报上市。 证 公司公告 券 研 （1）亚盛医药-B：自愿公告新型 Bcl-2 抑制剂利沙托克拉（利生妥®）正式 获中国国家药品监督管理局批准，用于治疗成人慢性淋巴细胞白血病/小淋巴 细胞淋巴瘤患者； 究 （2）药明康德：2025 年半年度业绩预增公告； 报 相关研究报告 （3）甘李药业：2025 年半年度业绩预增公告； 告 录有望出台——医药生物行 （4）艾力斯：自愿披露关于甲磺酸伏美替尼片 EGFR 20 外显子插入突变 NSCLC 二线 ...

36氪 . 36氪是服务中国新经济参与者的卓越品牌和开创性平台，提供新锐深度的商业报道，强调趋势和价值，我们的slogan是：让一部分人先看到未来。 文 ｜ 张钰铮 编辑 ｜ 方婷 封面来源 ｜reuters 为了返老还童，跟儿子换血，当过两年摩门教传教士，每天吃上百片补剂，被称为"姨化吸血鬼"。和这位追求永生的硅谷狂人比，各位是更信他，还是更信 秦始皇？ 编者荐语： 日经中文网与36氪开展内容交换合作。将精选36氪的精彩独家财经、科技、企业资讯，与读者分享。 以下文章来源于36氪 ，作者张钰铮 方婷 但当我们采访到这位布莱恩·约翰逊时，他却说， 他想要的，既不是长生不老，也不是青春永驻。 追求抗衰的目的是什么？"不要死" 在采访中，布莱恩·约翰逊问过这样一个问题，未来的人类会如何评价本世纪？对此他的答案是： 1、人类孕育出了超级人工智能；2、人类意识到自己将不 再死亡。 虽然"不再死亡"并不意味着"永生"，但人类如今能看到一个非常清晰的前景：通过先进技术，尤其是人工智能，我们不用再去设想自己只能活到70岁、80 岁、90岁或100岁，我们甚至不知道生命的终点会在哪里。 "在这个由AI引领的新世界中，我决定成 ...

港股收盘，恒生指数收涨0.46%，恒生科技指数收涨0.61%。中资券商股走强，中州证券(01375.HK)收 涨47%；生物医药概念大幅回升，药明康德(02359.HK)收涨10%；芯片、保险、加密货币等概念涨幅居 前。 ...

Group 1 - The Sci-Tech Innovation 50 Index opened slightly higher on July 11, closing at 994.45 points with an increase of 1.48% and a trading volume of approximately 31.3 billion yuan [1] - The Sci-Tech Comprehensive Index also opened slightly higher, closing at 1230.61 points with a rise of 1.27% and a total trading volume of about 110.3 billion yuan, marking a significant increase in trading volume [1] - The closing point of the Sci-Tech Comprehensive Index on July 11 was higher than the closing point on June 30, 2025, setting a new stage closing high [1] Group 2 - Nearly 70% of stocks on the Sci-Tech Board rose on July 11, with strong performance in the pharmaceutical and medical sectors, including stocks like Haooubo and Yifang Bio, which rose over 10% [1] - The average increase for 589 stocks on the Sci-Tech Board was 1.08%, with an average turnover rate of 2.57% and a total trading volume of 110.28 billion yuan [1] Group 3 - Individual stock performance saw Haooubo, Borui Data, and Shangwei New Materials reaching approximately 20% limit up, while Qinchuan Internet of Things experienced a decline of 11.16%, the largest drop [2] - In terms of trading volume, Hanwujing topped with 6.359 billion yuan, while ST Pava had the lowest at 664.49 million yuan [3] - The turnover rate for Yitang Co. was 30.84%, the highest, while Longteng Optoelectronics had the lowest turnover rate at 0.17% [4]

点击查看公告原文>> 来源：新浪港股-好仓工作室 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 2025年7月9日，基石药业（股份代号：2616）公告称，通过一般授权以"配售新股"方式融资，配售 100,000,000股（约1.0亿股），募集约4.7亿港元（扣除费用后净得约4.7亿港元）。本次融资由摩根士丹 利担任独家整体协调人、独家配售代理及独家账簿管理人。 基石药业是一家专注于抗肿瘤药物研发的创新型生物制药公司。所得款项中，约4.2亿港元将用于与集 团"管线2.0"中的资产相关的进一步研发，约0.5亿港元将用于其他一般公司用途。本次发行根据股东大 会授予的一般授权实施，预计于2025年7月16日完成。 配售新股配售价4.72港元，较前一交易 ...

Core Viewpoint - Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. has submitted its IPO application to the Hong Kong Stock Exchange, aiming for a listing under the 18A rules, with CITIC Securities as the sole sponsor. This marks the second submission after the previous application lapsed [1][2]. Company Overview - Founded in 2017, Jinfang Pharmaceutical focuses on the development of innovative drugs for oncology, autoimmune, and inflammatory diseases. The company's core product, GFH925, a small molecule selective KRAS G12C protein inhibitor, received approval for marketing in August 2024 [1][3]. Market Competition - The KRAS G12C inhibitor market is becoming increasingly competitive, with several competitors already launched and others in late-stage clinical trials. The commercial prospects for GFH925 are uncertain due to the poor sales performance of existing competitors [2][5][6]. Product Development and Approval - GFH925 is the first KRAS G12C inhibitor approved in China for the second-line treatment of advanced non-small cell lung cancer (NSCLC). However, the product's commercial value remains to be validated [3][6]. Financial Performance - Jinfang Pharmaceutical has reported revenues of 105 million yuan, 73.73 million yuan, 105 million yuan, and 82.14 million yuan for the years 2022, 2023, and the first four months of 2025, respectively. The company has incurred total losses exceeding 1.5 billion yuan over three and a half years [9][10][11]. Patent Risks - GFH925 faces potential patent risks, with only one of five patent families granted authorization. The company has entered agreements to mitigate these risks, but the deletion of risk warnings from the updated prospectus raises concerns [7][8]. Collaborations and Agreements - The collaboration with Innovent Biologics regarding GFH925 has changed, requiring Jinfang Pharmaceutical to pay a termination fee of 20 million USD due to the alteration of rights concerning the product's commercialization [10][11].